SecBot SecBot
SECBOTREPLAY Home › Report › MIRM

MIRM · Mirum Pharmaceuticals announced positive Phase 2b results for volixibat…

Mirum Pharmaceuticals, Inc. · 8-K filed May 4, 2026 at 08:00 ET

At the news

BULLISHIMPACT 6/10

8-K filed May 4, 2026 at 08:00 ET

Mirum Pharmaceuticals announced positive Phase 2b results for volixibat in PSC, meeting the primary endpoint with high statistical significance (p<0.0001) and a robust placebo-adjusted improvement in pruritus. The company plans a pre-NDA meeting with the FDA in summer 2026 and an NDA submission in H2 2026, positioning volixibat as a potential first treatment for cholestatic pruritus in PSC.

  • Primary endpoint met in VISTAS Phase 2b study of volixibat in PSC (p<0.0001).
  • Placebo-adjusted improvement of 1.64 points on Adult ItchRO scale.
  • 55.6% of volixibat patients achieved 2-point reduction vs 26.3% for placebo (p=0.0019).
  • Pre-NDA meeting with FDA scheduled for summer 2026; NDA submission planned H2 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access